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Cytotoxic chemotherapy before and after radiotherapy
compared with radiotherapy followed by chemotherapy in
the treatment of small-cell carcinoma of the bronchus: The
results up to 36 months
REPORT TO THE MEDICAL RESEARCH COUNCIL BY ITS LUNG CANCER WORKING PARTY
ON THE THIRD SMALL-CELL STUDY.*
Summary This report compares the results up to 36 months of two sequences of radiotherapy and
chemotherapy for small-cell anaplastic carcinoma of the bronchus, of limited extent (defined below). A total
of 91 patients were allocated at random to treatment with radiotherapy to the primary site followed by 10
pulses of chemotherapy using cyclophosphamide, methotrexate and CCNU (RC), and 95 to two pulses of the
same chemotherapy, followed by radiotherapy, followed by 8 pulses of chemotherapy (CRC).
The median survival times were 36 weeks for the RC series and 45 weeks for the CRC series but there was
no statistically significant difference in survival (P=0.9, log-rank test). At 12 months, 32 (35%) of the RC
and 38 (40%) of the CRC patients were alive, at 24 months, 8 (9%) and 4 (4%), and at 36 months, 7 (8%)
and 1 (1%) respectively. The patients' general condition, grade of activity and respiratory assessment
correlated significantly with survival. Of 38 patients reported to be in "excellent" condition at the start of
treatment, 6 (16%) were alive at 3 years.
Athough there was evidence that the onset of metastases was slightly delayed in the CRC series, this
difference had disappeared by 12 months.
Considerable advances have been made in the
management of small-cell anaplastic carcinoma of
the bronchus over recent years (reviewed by Hansen
1980; 1982; and by Bunn & Ihde, 1981). The
management of disease thought to be limited to the
primary site and regional lymph nodes has usually
involved combinations of radiotherapy and
chemotherapy, although recently the role of
radiotherapy has been questioned (reviewed by
Bleehen et al., 1983).
The second small-cell study conducted by the
Medical Research Council (MRC) Lung Cancer
Working Party demonstrated improved survival for
patients with limited disease when radiotherapy to
the primary site was followed by chemotherapy
with cyclophosphamide, methotrexate and CCNU
(MRC Lung Cancer Working Party, 1979; 1981).
However, long-term disease-free survival was poor,
being only 2% and 3% respectively for the radio-
therapy alone and the radiotherapy plus
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chemotherapy series at 3 years. Chemotherapy was
not started until at least 3 weeks after completion
of the radiotherapy. This delay may have been
partly responsible for the small production of long-
term survivors. The present study was therefore
undertaken to examine, in a randomised multi-
centre study, whether, in patients with "limited"
disease (as defined below), treatment with
radiotherapy followed by chemotherapy (using the
same regimen as in the second MRC small-cell
study) could be improved by giving two pulses of
the chemotherapy before the radiotherapy. This
report gives the results at three years for the
complete intake of 186 eligible pateints, and relates
them to the results from other recent studies.
Plan and conduct of the study
Eligibility
Patients aged 70 years or less were eligible if they
had previously untreated, histologically or cyto-
logically proven small-cell carcinoma, and if the
disease, on clinical and radiographic evidence alone,
was "limited" in extent, that is, confined to the soft
tissue of one hemithorax, the mediastinum, and the
ipsilateral and contralateral scalene and lower
cervical lymph nodes. Patients were not eligible if
they had superior vena cava obstruction, poor renal
function (blood urea concentration >9.5mmol -1),
or serious disease contraindicating radiotherapy or
chemotherapy.
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Histological diagnosis
The diagnosis was made by the pathologist from
the referring centre according to the WHO
classification (Kreyberg et al., 1967) on a specimen
obtained from bronchial, pleural, lung, mediastinal,
or cervical node biopsy, bronchial brushings, or
sputum cytology. All the specimens were later
examined by a single reference pathologist for
confirmation of the cell type.
Pretreatment investigations
The pretreatment investigations included a postero-
anterior chest radiograph, measurement of the
blood haemoglobin and urea concentrations, total
white cell and platelet counts, and liver function
tests (serum concentrations of bilirubin, alkaline
phosphatase, and alanine aminotransferase or
equivalent enzyme). Marrow examination and
radioactive isotope scans for metastases were done
routinely in only a few centres, and so the results of
these investigations were not taken into account in
assessing the eligibility of patients for admission.
Treatment
Patients were randomly allocated to treatment with
either:
RC series Radiotherapy followed by 10 pulses of
chemotherapy, or
CRC series Two pulses of chemotherapy, followed
by radiotherapy, followed by 8 pulses of chemo-
therapy.
Radiotherapy consisted of a megavoltage midline
dosage of 30Gy given in 15 fractions over 3 weeks,
or a suitable biological equivalent. It was delivered
through opposed portals to the primary site and the
mediastinal lymph nodes, the field extending at
least from the suprasternal notch to 2cm below the
carina and encompassing the full width of the
mediastinum and lung hila.
Chemotherapy consisted of 10 alternating 3-drug
and 2-drug pulses at 3-week intervals (interrupted
by the radiotherapy starting 3 weeks after the 2nd
pulse in the CRC series). It could be stopped
before, or prolonged beyond, 10 pulses if the
patient's progress warranted it. Cyclophosphamide
500mgm-2 and methotrexate 50mgm-2 were
given by i.v. injection on each occasion; CCNU
50mgm-2 was given p.o. on the first and alternate
pulses thereafter, i.e. every 6 weeks for 5 pulses.
Metoclopromide 10mg by i.v. injection, or other
suitable antiemetic, was given with each pulse.
There was an interval of 3 weeks between the end
of the radiotherapy and the following pulse of
chemotherapy.
Reports and investigations
In addition to a pretreatment report, a report on
each patient was completed at each attendance for
treatment, monthly up to 24 months, and then once
every 3 months. These reports included information
on the allocated therapy, additional palliative
therapy, any adverse reactions encountered,
metastases, the blood haemoglobin concentration
and total white cell and platelet counts.
Results
Patients in the study
Between April 1977 and January 1981, 190 patients
were admitted from 19 centres in the United
Kingdom; 4 (2 RC, 2 CRC) were excluded because
the histology was not small-cell at independent
assessment. There remain 186 patients (91 RC, 95
CRC) for analysis, including 18 RC and 21 CRC
patients whose diagnosis was based on sputum
cytology alone, and 2 RC and 4 CRC patients for
whom the histological slides submitted to the
reference pathologist were inadequate to confirm
the diagnosis.
Condition on admission
The distributions (Table I) of sex, age, and clinical
status were similar in the 2 series. The majority
(70%) of the patients were male, 67% were aged
between 55 and 70 years, 76% were considered by
their physician to be in "excellent" or "good"
general condition, for 90% the grade of activity
was 1 or 2, and for 67% the grade of respiratory
assessment was 1 or 2, that is, normal or nearly
normal.
Survival to 36 months
The follow-up to 36 months is complete for all the
patients. The survival curves (Figure 1) showed that
there was no statistically significant difference
between the 2 series (P=0.9, log-rank test). There
appears to be a slightly prolonged survival for the
CRC series initially, but there were more long-term
survivors in the RC series. The median survival was
36 weeks for the RC series and 45 weeks for the
CRC series, but the 95% confidence limits are wide
(30 to 47 in the RC and 42 to 52 in the CRC
series). At 12 months, 32 (35%) of the RC and 38
(40%) of the CRC patients were alive, at 24
months, 8 (9%) and 4 (4%) and at 36 months 7
(8%) and 1 (1%) respectively. For 7 of the 8
survivors at 36 months, the diagnosis had been
confirmed by the reference pathologist; for the 8th
(RC) inadequate slides had been submitted for
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of the 186 patients assessed on
admissiona
RC CRC Total
Condition No. % No. % No. %
Sex: male 66 73 64 67 130 70
Age (years):
<45
45-54
55-64
65-
General condition:
excellent
good
fair
poor
very poor
Activity:
grade 1. normal
2. restricted
3. confined to
home/hospital
4. bedridden
Respiratory assessment:
grade 1. climbs hills and stairs
without dyspnoea
2. walks on flat at
normal pace without
dyspnoea
3. walks more than
100 yards at own
pace without
dyspnoea
4. dyspnoea on
walking less than
100 yards
5. dyspnoea on mild
exertion (e.g.
undressing)
3
26
35
26
21
51
17
2
0
50
32
9
0
3
29
39
29
23
56
19
2
0
55
35
10
0
6
26
46
16
17
52
22
2
1
55
31
8
1
6
28
49
17
18
55
23
2
1
58
33
8
1
9 5
52 28
81 44
42 23
38
103
39
4
1
105
63
17
1
21
56
21
2
1
56
34
9
I
26 29 19 20 45 24
36 40 44 46 80 43
12 13 19 20 31 17
14 15 9 9 23 12
3 3 4 4 7 4
aInformation was not available on age for 1 RC and 1
CRC patient or on clinical condition for 1 CRC'patient.
For the 8 survivors at 36 months, the general
condition pretreatment was "excellent" for 6 and
"good" for 2, the grade of activity normal for 6
and restricted for 2, and the respiratory assessment
normal for 5 and "able to walk on the level
without dyspnoea" for 3.
Carcinoma was the underlying cause of death in
all except 5 RC and 4 CRC patients, in whom the
main cause was drug toxicity (3 RC, 2 CRC),
concomitant lymphoma (1 RC), pulmonary
embolism (1 RC), and myocardial infarction (2
CRC).
Prognosticfactors
Regression analyses to test whether age, sex,
regimen, and pretreatment weight, haemoglobin
concentration, white cell count, platelet count,
general condition, grade of activity, and respiratory
assessment affected survival, showed that only
general condition (P<0.001), grade of activity
(P<0.001) and respiratory assessment (P<0.005)
correlated significantly. However, in a stepwise
regression analysis to test whether combinations of
the above factors were better indicators of
prognosis, only general condition had a significant
effect, grade of activity and respiratory assessment
being so closely related to it that they added
nothing. The median survivals for the 38 patients in
"excellent" condition pretreatment, the 103 in
"good" condition, and the 39 in "fair" condition
were 57, 41 and 32 weeks respectively, survival for
those in "excellent" condition being significantly
longer (log-rank test) than for those in "good"
(P<0.001) or "fair" (P<0.001) condition. At 36
months, 6 (16%) of the 38 in "excellent" condition
pretreatment were alive compared with 2 (2%) of
the 103 in "good" condition, and none of the 39 in
"fair", the 4 in "poor" or the 1 in "very poor"
condition.
Evidence ofprimary growth at death
Of the 84 RC and 94 CRC patients who died
during the 36 months, 48 (57%) and 53 (56%) had
evidence at the time of death of persistence or
recurrence of the primary growth, of whom 31 and
42 respectively also had distant metastases.
Confirmation of persistence or recurrence of the
primary growth was obtained in 8 of the 14 RC
and 6 of the 8 CRC patients who had an autopsy.
Metastases
Distant metastases (Table II) occurred with a
similar frequency in the 2 series, namely in 70% of
the RC and 76% of the CRC patients (P=0.5), the
distribution of the sites also being similar.
Table H Occurrence and site ofdistant metastases during
36 months
RC CRC
Site No. % No. %
Liver 35 38 47 49
Bone 25 27 28 29
Brain 16 18 20 21
Opposite lung 11 12 18 19
Distant lymph nodes 7 8 7 7
Skin 8 9 3 3
Other 6 7 5 5
Total patients with
distant metastases 64 70 72 76
Total patients 91 100 95 100
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58 (64%)
72 (76%)
32 (35%) 14 (15%)
38 (40%) 11 (12%)
RC - *." CRC
I I Il r. ........... .
6 12 18 24
Time (months) from allocation
Figure 1 Survival from allocation in 91 RC and 95 CRC patients.
However, there was evidence that the onset of
metastases was slightly delayed in the CRC series
(Table III). By 3 months, 29% of the RC compared
with 16% of the CRC patients had metastases, and
by 6 months 38% and 31% respectively, but by 12
months this difference had disappeared, and at 36
months 70% of the RC but 76% of the CRC
patients had metastases. A similar pattern is seen
for the 2 commonest sites of metastases, viz. liver
and bone.
Table III Cumulative percentages ofpatients with distant
metastases
Cumulative percentage ofpatients with
distant metastases by month:
3 6 9 12 24 36
Site RC RC RC CRC RC CRC RC CRC RC CR( RC CRC
Any site 29 16 38 31 52 45 60 60 69 75 70 76
Liver 18 8 24 18 26 27 33 35 38 48 38 49
Bone I11 15 9 24 18 26 24 27 28 27 29
Additional palliative treatment
During the first 12 months, additional palliative
radiotherapy was given to 19 (21%) of the 91 RC
and 26 (27%) of the 95 CRC patients. The sites
irradiated were bone in 24 (11 RC, 13 CRC), neck
or mediastinum in 12 (5 RC, 7 CRC), skull or
brain in 10 (4 RC, 6 CRC), thorax in 9 (4 RC, 5
CRC) and skin in 3 (1 RC, 2 CRC). During the
second and third years additional radiotherapy was
given to a further 7 (8%) of the RC and 15 (16%)
of the CRC patients, the sites being bone in 6 (1
RC, 5 CRC), neck or mediastinum in 9 (1 RC, 8
CRC), skull or brain in 4 (3 RC, 1 CRC), and
thorax in 9 (3 RC, 6 CRC). Thus, during the 36
months, additional palliative radiotherapy was
given to 26 (29%) of the RC and 41 (43%) of the
CRC patients (P=0.055).
A total of 11 (12%) RC and 15 (16%) CRC
patients continued their allocated chemotherapy
beyond 10 pulses. Alternative cytotoxic chemo-
therapy was given to 6 RC and 8 CRC patients,
because the allocated chemotherapy was failing or
Patients alive
RC 91 (100%)
CRC 95 (100%)
100
8 (9%)
4 (4%)
80 _
7 (8%)
2 (2%)
7 (8%)
1 (1%)
60H
0)
a)
C)
0)
0)
Cu
co
C.)
0~
40
20H
0 30 36
I
- I
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had failed, and to 1 RC patient because of a
lymphoma.
Adverse reactions
Adverse reactions occurred with a similar frequency
in the 2 series (Table IV), being reported in 81% of
the RC and 82% of the CRC patients. Nausea with
or without vomiting was the commonest reaction,
occuring, in spite of the routine use of antiemetics,
in 70% of the RC and 79% of the CRC patients.
Mouth ulcers occurred in 36% and 31%
respectively, and haematological reactions in 49%
and 40% respectively, the commonest of the latter
being leucopenia, which occurred in 37% of the RC
and 29% of the CRC patients. Pancytopenia
occurred in 4% of the RC and 1% of the CRC
patients. In all, 10 of the RC and 7 of the CRC
patients were given 1 or more blood transfusions,
and 1 of the RC and 3 of the CRC patients had
severe infections attributed to leucopenia: these
were bronchopneumonia in the RC patient and 2 of
the CRC patients, and staphylococcal septicaemia
in 1 CRC patient. In 3 RC and 2 CRC patients,
drug toxicity was considered to be the main cause
of death. In the RC series, 1 patient had
thrombocytopenia for the first time during the
second year, and in the CRC series, 1 patient had
vomiting and 3 patients had haematological
reactions for the first time during the second year,
all the other reactions occurring during the first 12
months.
Table IV Adverse reactions reported during 36 months
RC CRC
Reaction No. % No. %
Nausea without vomiting 12 13 15 16
Vomiting 52 57 60 63
Mouth ulcers 33 36 29 31
Rash 7 8 12 13
Haematological reactions:
total 45 49 38 40
anaemia (Hb<9.Og/dl) 15 16 17 18
leucopenia (WBC<3 x 109 V1) 34 37 28 29
thrombocytopenia (platelets
<100x 1091-1) 18 20 14 15
pancytopenia 4 4 1 1
Other 4 4 7 7
Total patients with reactions 74 81 78 82
Total patients 91 100 95 100
In neither series was any late spinal cord damage
reported.
Quality oflife
At 6 and at 12 months (Table V), the quality of life
assessed by the physician in terms of general
condition, grade of physical activity and respiratory
assessment, was similar in the 2 series.
Table V Clinical condition
At6months 2
RC CRC
General condition:
excellent
good
fair
poor
very poor
not assessed
Activity grade:'
1.
2.
3.
4.
not assessed
Respiratory assess-
ment grade:a
1.
2.
3.
4.
5.
not assessed
7
25
17
6
0
3
20
31
4
0
3
7
24
16
6
2
3
11
31
21
5
0
4
29
30
10
0
3
17
29
11
9
3
3
At 12 months
RC CRC
6
9
7
8
0
2
11
15
4
0
2
5
13
5
3
4
2
4
12
12
2
2
6
13
14
4
1
6
4
13
8
4
2
7
Patients assessed 58 72 32 38
aDefined in Table I.
Progress beyond 36 months
Of the 7 RC and 1 CRC patients still alive at 3
years, 1 RC patient died during month 41; the
remaining 6 RC patients are alive at 40, 47, 57, 59,
63 and 69 months and the CRC patient at 44
months. Of these 7, 1 RC patient has an enlarging
primary cancer and distant metastases; the other 6
are all well and free of metastases.
Discussion
The limited progress in the management of small-
cell carcinoma of the bronchus over the past few
years has largely resulted from improvements in
chemotherapy. Assessments of the proportion of
long-term survivors (for 2 years or more) in
patients with limited disease range from 25%
(Oldham & Greco, 1980) to a more generally
observed figure of 5-10% (Bunn & Ihde, 1981;
Hansen, 1982). The mean duration of survival in all
patients, that is, including those with extensive
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disease, is usually 9-12 months (Hansen, 1982), the
great majority of patients still die of their disease,
and there is great scope for improvement in the
efficacy of treatment.
The present study was designed to test the
importance of the sequence of radiotherapy and
chemotherapy. In the second MRC study (MRC
Lung Cancer Working Party, 1979; 1981) patients
were given chemotherapy after the radiotherapy.
That sequence might be criticised as permitting the
early extension of as yet undetected metastases and
the development of metastases at new sites during
the 6 weeks before the chemotherapy was started.
Data in favour of this concept have been
reviewed (Salazar & Creech, 1980; Bleehen et al.,
1983) and are inconclusive. There is some indirect
evidence from the studies of Gilby et al. (1977) and
Choi & Carey (1976) in favour of the sequence in
which the treatment regimen starts with chemo-
therapy. There is one other randomised study
conducted by the Swiss Group for Clinical Cancer
Research (SAKK) which showed no significant
difference between the two treatment schedules
(Brunner et al., 1978; P. Alberto, personal
communication, 1981). However, the relevant
treatment subgroups in the latter study were small.
The results reported from our present study suggest
no significant survival advantage for either of the
radiotherapy and chemotherapy sequences, namely
radiotherapy followed by chemotherapy, or 2 pulses
of chemotherapy and then radiotherapy followed
by the rest of the chemotherapy. Toxicities of
treatment were similar in both series, and to that of
the radiotherapy followed by chemotherapy series
in the second MRC small-cell study (MRC Lung
Cancer Working Party, 1979; 1981).
The overall survival results are not as good as
some now being reported (Bunn & Ihde, 1981;
Hansen, 1982). This may be due to differences in
the selection of patients, in the choice of drug
regimen and in the nature of the radiotherapy. In
the present study, the definition of limited stage
disease was made on the basis of conventional
clinical and radiological examination alone. Because
it was a multi-centre study, bone marrow
examination, peritoneoscopy, and isotopic or CT
scans, were not done routinely. Hence, even when
available, results from these investigations were not
included in the staging assessment. Undoubtedly
some of the patients will, in fact, have started with
extensive disease by current convention. This may
well have biased the results towards the lower
figures seen in extensive disease for which median
survivals of from 3-14 months and 2-year disease-
free survivals of the order of 1% have been
reported (Bunn & Ihde, 1981; Hansen, 1982).
In this context, it is of interest to note that 6
(16%) of our patients regarded as being in
"excellent" condition pretreatment, were still alive
at 3 years. No other results from the data analysed
throw any further light on possible prognostic
factors.
It is of interest to note that age was not of
prognostic significance in this study, in contrast to
the findings of the second MRC small-cell study
(MRC Lung Cancer Working Party, 1981). This is
in keeping with the variability of its significance in
other studies.
The analysis of the sites of recurrence gives some
indication of the possible reasons for treatment
failure. The high incidence (57%) of patients with
evidence of persistent or recurrent primary disease
at the time of death indicates that this is still a
major problem as has been reported in other series
(Bleehen, 1980; Salazar & Creech, 1980; Bunn &
Ihde, 1981), although concurrent metastatic spread
is often the cause of death. A higher radiation dose
might possibly have reduced this incidence, but a
review of experience with higher doses (Bleehen et
al., 1983) does not support this view.
The frequency of brain metastases, reported in 35
(20%) of the patients, is of the same order as in
other series when prophylactic cranial irradiation is
not given (Bunn & Ihde, 1981; Bleehen et al., 1983).
However, its addition has not influenced survival
time in several randomised studies and the fact that
it was not used is unlikely to have affected the
results in the present study.
The high incidence of liver metastases (44% in
the 2 series combined) also indicates the need for a
more effective chemotherapy regimen. Several new
drug regimens which attempt to reduce this high
incidence include other active agents such as
vincristine, adriamycin, and VP16-213, given either
as courses of the same drugs throughout, or as
alternating regimens, or with maintenance regimens
(Hansen, 1980; 1982; Aisner et al., 1983).
Several recent studies have demonstrated the
feasibility of giving radiotherapy and chemotherapy
simultaneously (Johnson et al., 1978; Greco et al.,
1979; Cohen et al., 1980). This attempt to improve
results is now being investigated prospectively in a
randomised study by the Cancer and Leukaemia
Group B in the United States. There are also
several studies investigating whether there is any
need at all for local radiotherapy in patients with
limited disease. A final answer to this latter
question is still awaited but a recent consensus
suggests that radiotherapy might still have a role in
controlling disease at the primary site (Bleehen et
al., 1983).
The management of small-cell carcinoma of the
lung remains under intense scrutiny. Innovative
pilot studies followed by carefully documentedCHEMO-RADIOTHERAPY OF LUNG SMALL-CELL CARCINOMA 761
randomised studies involving adequate numbers of
patients will hopefully lead to continued
improvement in results.
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